Myogen MYOG
-
New Morningstar Analyst Report - Gilead Sciences
… B. The acquisitions of Corus Pharma, Myogen , CV Therapeutics, Arresto Biosciences ..... paid a significant premium to acquire Myogen , and the failure of darusentan puts even ..... infectious disease territory, including Myogen , CV Therapeutics, and smaller, development …
-
New Credit Rating: Gilead Sciences
… debtholders . In 2006 , Gilead acquired Myogen , and in 2009 , it acquired CV Therapeutics . The recent failure of darusentan ( a Myogen compound for hypertension ) highlights ..... With that failure , the purchase price of Myogen looks quite high and puts pressure on …
-
New Morningstar Analyst Report - Gilead Sciences
… paid a significant premium to acquire Myogen , and the recent failure of darusentan ..... with the acquisitions of Corus Pharma, Myogen and CV Therapeutics . Gilead uses a specialized ..... with the $2.5 billion acquisition of Myogen in 2006 and the $1.4 billion acquisition …
-
Gilead Offers to Buy CV Therapeutics
… with Gilead's drug portfolio. Its young cardiovascular franchise--which has its roots in the firm's 2006 acquisition of Myogen , including pulmonary hypertension drug Letairis as well as hypertension drug candidate darusentan--is now poised for even …
-
Five Firms Big Pharma Should Buy Next
… Sometimes a firm looks to expand into new therapeutic areas, such as when HIV expert Gilead GILD bought cardiopulmonary firm Myogen , Merck MRK bought Sirna Therapeutics for its innovative new RNA interference technology, or when Abbott ABT bought Kos Pharmaceuticals …
-
Gilead to Acquire Myogen at Premium
… its $2.5 billion acquisition of Myogen MYOG , Gilead Sciences GILD is taking ..... biotech is an ideal choice to shepherd Myogen 's ambrisentan to commercialization ..... share reflects a 50% premium to Myogen 's closing price before the offer …
-
Gilead to Acquire Myogen
… Sciences GILD announced Monday that it will acquire Myogen MYOG in a great deal for Myogen shareholders. We'll more than double our fair value estimate for Myogen to reflect the offer price. We'll re-examine …
-
Future Drugs Critical to Myogen
Myogen 's MYOG second-quarter results held few surprises ..... the real story lies in the future of Myogen 's drug pipeline. Ambrisentan for pulmonary ..... for ambrisentan to be a runaway success. Myogen initiated Phase III clinical trials for …
-
Myogen Partners Up
Myogen MYOG released fourth-quarter earnings Monday that didn ..... outside the United States. This agreement also extends to Myogen the U.S. rights to Glaxo's Flolan product. Myogen plans to use future Flolan sales to establish a U.S …
-
Morningstar's 2006 Contrarian Portfolio--Part 2
… weighted) 1,010 228.25 S&P 500 10.88 Outperformance 217.37 2005's 10 Best Performers Rank 2005 Return ( % ) Myogen MYOG 1,423 272.99 New River Pharmaceuticals NRPH 1,361 246.79 Great A&P Tea GAP 828 210.05 aQuantive AQNT 796 …